{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:14:10Z","timestamp":1781777650485,"version":"3.54.5"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00108-024-01728-w","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:02:12Z","timestamp":1718888532000},"page":"642-655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Schilddr\u00fcsenkarzinome\u00a0\u2013 Rolle internistischer Systemtherapien","Thyroid carcinomas: the role of systemic therapies in internal medicine"],"prefix":"10.1007","volume":"65","author":[{"given":"Tim","family":"Brandenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kroi\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"1728_CR1","doi-asserted-by":"publisher","DOI":"10.1530\/erc-22-0293","author":"C Christofer Juhlin","year":"2023","unstructured":"Christofer Juhlin\u00a0C, Mete\u00a0O, Baloch\u00a0ZW (2023) The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer. https:\/\/doi.org\/10.1530\/erc-22-0293","journal-title":"Endocr Relat Cancer"},{"key":"1728_CR2","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin\u00a0JA, Wells\u00a0SA (2016) Biologic and clinical perspectives on thyroid cancer. N\u00a0Engl J Med 375:1054\u20131067","journal-title":"N Engl J Med"},{"key":"1728_CR3","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1089\/thy.2015.0104","volume":"25","author":"I Ganly","year":"2015","unstructured":"Ganly\u00a0I et\u00a0al (2015) Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid 25:1106\u20131114","journal-title":"Thyroid"},{"key":"1728_CR4","doi-asserted-by":"publisher","DOI":"10.1530\/etj-22-0021","author":"J Tong","year":"2022","unstructured":"Tong\u00a0J et\u00a0al (2022) Poorly differentiated thyroid carcinoma: a\u00a0clinician\u2019s perspective. Eur Thyroid\u00a0J. https:\/\/doi.org\/10.1530\/etj-22-0021","journal-title":"Eur Thyroid J"},{"key":"1728_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1210\/jc.2012-2458","volume":"98","author":"FA Verburg","year":"2013","unstructured":"Verburg\u00a0FA et\u00a0al (2013) Life expectancy is reduced in differentiated thyroid cancer patients \u2265\u202f45\u00a0years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J\u00a0Clin Endocrinol Metab 98:172\u2013180","journal-title":"J Clin Endocrinol Metab"},{"key":"1728_CR6","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante\u00a0C et\u00a0al (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J\u00a0Clin Endocrinol Metab 91:2892\u20132899","journal-title":"J Clin Endocrinol Metab"},{"key":"1728_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen\u00a0BR et\u00a0al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1\u2013133","journal-title":"Thyroid"},{"key":"1728_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/thy.2018.0597","volume":"29","author":"MR Tuttle","year":"2019","unstructured":"Tuttle\u00a0MR et\u00a0al (2019) Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a\u00a0joint statement from the American thyroid association, the European association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the European thyroid association. Thyroid 29:461\u2013470","journal-title":"Thyroid"},{"key":"1728_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1007\/s00104-020-01284-7","volume":"91","author":"T Brandenburg","year":"2020","unstructured":"Brandenburg\u00a0T, F\u00fchrer\u00a0D (2020) Systemic treatment of metastasized thyroid cancer\u2014approved treatments and new approaches. Chirurg 91:1038\u20131043","journal-title":"Chirurg"},{"key":"1728_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"Filetti\u00a0S et\u00a0al (2019) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1856\u20131883","journal-title":"Ann Oncol"},{"key":"1728_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000502229","volume":"8","author":"L Fugazzola","year":"2019","unstructured":"Fugazzola\u00a0L et\u00a0al (2019) 2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid\u00a0J 8:227\u2013245","journal-title":"Eur Thyroid J"},{"key":"1728_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose\u00a0MS et\u00a0al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic diff erentiated thyroid cancer: a\u00a0randomised, double-blind, phase\u00a03\u00a0trial. Lancet 384:319\u2013328","journal-title":"Lancet"},{"key":"1728_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger\u00a0M et\u00a0al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N\u00a0Engl J Med 372:621\u2013630","journal-title":"N Engl J Med"},{"key":"1728_CR14","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas\u00a0ME, Ryder\u00a0M, Jimenez\u00a0C (2019) Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev 40:1573\u20131604","journal-title":"Endocr Rev"},{"key":"1728_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/ERC-18-0049","volume":"25","author":"AG Gianoukakis","year":"2018","unstructured":"Gianoukakis\u00a0AG, Dutcus\u00a0CE, Batty\u00a0N, Guo\u00a0M, Baig\u00a0M (2018) Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer 25:699\u2013704","journal-title":"Endocr Relat Cancer"},{"key":"1728_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1089\/thy.2017.0205","volume":"28","author":"A Berdelou","year":"2018","unstructured":"Berdelou\u00a0A et\u00a0al (2018) Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 28:72\u201378","journal-title":"Thyroid"},{"key":"1728_CR17","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1089\/thy.2019.0246","volume":"29","author":"HS Oh","year":"2019","unstructured":"Oh\u00a0HS et\u00a0al (2019) Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment: a\u00a0Korean multicenter study. Thyroid 29:1804\u20131810","journal-title":"Thyroid"},{"key":"1728_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","volume":"118","author":"LD Locati","year":"2019","unstructured":"Locati\u00a0LD et\u00a0al (2019) Real-world efficacy and safety of lenvatinib: data from a\u00a0compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer 118:35\u201340","journal-title":"Eur J Cancer"},{"key":"1728_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8834148","author":"G Rendl","year":"2020","unstructured":"Rendl\u00a0G et\u00a0al (2020) Real-world data for lenvatinib in radioiodine-refractory differentiated thyroid cancer (RELEVANT): a\u00a0retrospective multicentric analysis of clinical practice in Austria. Int J Endocrinol. https:\/\/doi.org\/10.1155\/2020\/8834148","journal-title":"Int J Endocrinol"},{"key":"1728_CR20","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1089\/thy.2020.0206","volume":"31","author":"VF Koehler","year":"2021","unstructured":"Koehler\u00a0VF et\u00a0al (2021) Real-world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. Thyroid 31:1531\u20131541","journal-title":"Thyroid"},{"key":"1728_CR21","doi-asserted-by":"publisher","DOI":"10.1089\/THY.2022.0054","author":"M Kim","year":"2022","unstructured":"Kim\u00a0M et\u00a0al (2022) Lenvatinib compared with sorafenib as a\u00a0first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a\u00a0multicenter retrospective cohort study. Thyroid. https:\/\/doi.org\/10.1089\/THY.2022.0054","journal-title":"Thyroid"},{"key":"1728_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.e18075","author":"Z Peelay","year":"2022","unstructured":"Peelay\u00a0Z et\u00a0al (2022) Real-world analysis of use of lenvatinib in differentiated thyroid cancers. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.e18075","journal-title":"J. Clin. Oncol."},{"key":"1728_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/oncolo\/oyac065","volume":"27","author":"LJ Wirth","year":"2022","unstructured":"Wirth\u00a0LJ et\u00a0al (2022) Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit. Oncologist 27:565\u2013572","journal-title":"Oncologist"},{"key":"1728_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejca.2020.12.032","volume":"147","author":"M Tahara","year":"2021","unstructured":"Tahara\u00a0M et\u00a0al (2021) Impact of lung metastases on overall survival in the phase\u00a03 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 147:51\u201357","journal-title":"Eur J Cancer"},{"key":"1728_CR25","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1089\/thy.2020.0779","volume":"31","author":"MH Taylor","year":"2021","unstructured":"Taylor\u00a0MH et\u00a0al (2021) Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 31:1226\u20131234","journal-title":"Thyroid"},{"key":"1728_CR26","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1210\/clinem\/dgab731","volume":"107","author":"MS Brose","year":"2022","unstructured":"Brose\u00a0MS et\u00a0al (2022) A\u00a0randomized study of lenvatinib 18\u202fmg vs 24\u202fmg in patients with radioiodine-refractory differentiated thyroid cancer. J\u00a0Clin Endocrinol Metab 107:776\u2013787","journal-title":"J Clin Endocrinol Metab"},{"key":"1728_CR27","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1002\/cncr.31344","volume":"124","author":"LJ Wirth","year":"2018","unstructured":"Wirth\u00a0LJ et\u00a0al (2018) Treatment-emergent hypertension and efficacy in the phase\u00a03 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer 124:2365\u20132372","journal-title":"Cancer"},{"key":"1728_CR28","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","volume":"22","author":"MS Brose","year":"2021","unstructured":"Brose\u00a0MS et\u00a0al (2021) Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a\u00a0randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial. Lancet Oncol 22:1126\u20131138","journal-title":"Lancet Oncol"},{"key":"1728_CR29","doi-asserted-by":"publisher","unstructured":"Sherman E et\u00a0al Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: a\u00a0LIBRETTO-001 update STUDY DESIGN. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.038","DOI":"10.1016\/j.annonc.2022.01.038"},{"key":"1728_CR30","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth\u00a0LJ et\u00a0al (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N\u00a0Engl J Med 383:825\u2013835","journal-title":"N Engl J Med"},{"key":"1728_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"N Agrawal","year":"2014","unstructured":"Agrawal\u00a0N et\u00a0al (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676","journal-title":"Cell"},{"key":"1728_CR32","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","volume":"7","author":"KZ Thein","year":"2021","unstructured":"Thein\u00a0KZ, Velcheti\u00a0V, Mooers\u00a0BHM, Wu\u00a0J, Subbiah\u00a0V (2021) Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer 7:1074\u20131088","journal-title":"Trends Cancer"},{"key":"1728_CR33","doi-asserted-by":"publisher","first-page":"14035","DOI":"10.1007\/s00432-023-05134-x","volume":"149","author":"VF Koehler","year":"2023","unstructured":"Koehler\u00a0VF et\u00a0al (2023) NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer. J\u00a0Cancer Res Clin Oncol 149:14035\u201314043","journal-title":"J Cancer Res Clin Oncol"},{"key":"1728_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho\u00a0AL et\u00a0al (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N\u00a0Engl J Med 368:623\u2013632","journal-title":"N Engl J Med"},{"key":"1728_CR35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/thy.2022.0707","volume":"33","author":"J Wadsley","year":"2023","unstructured":"Wadsley\u00a0J et\u00a0al (2023) Results of the SEL-I-METRY phase\u00a0II trial on resensitization of advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. Thyroid 33:1119\u20131123","journal-title":"Thyroid"},{"key":"1728_CR36","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","volume":"21","author":"SM Rothenberg","year":"2015","unstructured":"Rothenberg\u00a0SM, McFadden\u00a0DG, Palmer\u00a0EL, Daniels\u00a0GH, Wirth\u00a0LJ (2015) Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res 21:1028\u20131035","journal-title":"Clin Cancer Res"},{"key":"1728_CR37","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1210\/jc.2018-01478","volume":"104","author":"LA Dunn","year":"2019","unstructured":"Dunn\u00a0LA et\u00a0al (2019) Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. J\u00a0Clin Endocrinol Metab 104:1417\u20131428","journal-title":"J Clin Endocrinol Metab"},{"key":"1728_CR38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/thy.2021.0565","volume":"32","author":"V Tchekmedyian","year":"2022","unstructured":"Tchekmedyian\u00a0V et\u00a0al (2022) Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a\u00a0pilot clinical trial. Thyroid 32:273\u2013282","journal-title":"Thyroid"},{"key":"1728_CR39","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","volume":"28","author":"M Weber","year":"2022","unstructured":"Weber\u00a0M et\u00a0al (2022) Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): a\u00a0single-center prospective two-arm study. Clin Cancer Res 28:4194\u20134202","journal-title":"Clin Cancer Res"},{"key":"1728_CR40","doi-asserted-by":"publisher","first-page":"A876","DOI":"10.1210\/jendso\/bvab048.1789","volume":"5","author":"S Leboulleux","year":"2021","unstructured":"Leboulleux\u00a0S et\u00a0al (2021) MERAIODE: a\u00a0redifferentiation phase\u00a0II trial with trametinib and dabrafenib followed by radioactive iodine administration for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a\u00a0BRAFV600E mutation (NCT 03244956). J\u00a0Endocr Soc 5:A876","journal-title":"J Endocr Soc"},{"key":"1728_CR41","first-page":"1124","volume":"33","author":"S Leboulleux","year":"2023","unstructured":"Leboulleux\u00a0S et\u00a0al (2023) MERAIODE: a\u00a0phase\u00a0II redifferentiation trial with trametinib and 131I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer. Thyroid 33:1124\u20131129","journal-title":"Thyroid"},{"key":"1728_CR42","first-page":"1184","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"Busaidy\u00a0NL et\u00a0al (2022) Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a\u00a0randomized, phase\u00a02, open-label multicenter trial. Thyroid 32:1184\u20131192","journal-title":"Thyroid"},{"key":"1728_CR43","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1089\/thy.2021.0524","volume":"32","author":"L Groussin","year":"2022","unstructured":"Groussin\u00a0L et\u00a0al (2022) Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer. Thyroid 32:594\u2013598","journal-title":"Thyroid"},{"key":"1728_CR44","doi-asserted-by":"publisher","first-page":"6512","DOI":"10.1200\/JCO.2020.38.15_suppl.6512","volume":"38","author":"B Haugen","year":"2020","unstructured":"Haugen\u00a0B et\u00a0al (2020) Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a\u00a0multicenter phase\u00a0II international thyroid oncology group trial. J\u00a0Clin Oncol 38:6512\u20136512","journal-title":"J. Clin. Oncol."},{"key":"1728_CR45","doi-asserted-by":"publisher","first-page":"S1086","DOI":"10.1016\/j.annonc.2020.08.1405","volume":"31","author":"B Haugen","year":"2020","unstructured":"Haugen\u00a0B et\u00a0al (2020) 1917P pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: results of a\u00a0multicenter phase\u00a0II international thyroid oncology group trial. Ann Oncol 31:S1086\u2013S1087","journal-title":"Ann Oncol"},{"key":"1728_CR46","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/cen.14617","volume":"96","author":"VF Koehler","year":"2022","unstructured":"Koehler\u00a0VF et\u00a0al (2022) Medullary thyroid cancer with ectopic Cushing\u2019s syndrome: a\u00a0multicentre case series. Clin Endocrinol 96:847\u2013856","journal-title":"Clin Endocrinol"},{"key":"1728_CR47","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1055\/a-0585-8097","volume":"143","author":"K Frank-Raue","year":"2018","unstructured":"Frank-Raue\u00a0K, Schott\u00a0M, Raue\u00a0F (2018) Recommendation for calcitonin screening in nodular goiter. Dtsch Med Wochenschr 143:1065\u20131069","journal-title":"Dtsch Med Wochenschr"},{"key":"1728_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/s-0043-122237","volume":"50","author":"S Allelein","year":"2018","unstructured":"Allelein\u00a0S et\u00a0al (2018) Measurement of basal serum calcitonin for the diagnosis of medullary thyroid cancer. Horm Metab Res 50:23\u201328","journal-title":"Horm Metab Res"},{"key":"1728_CR49","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1210\/jc.2009-2368","volume":"95","author":"A Machens","year":"2010","unstructured":"Machens\u00a0A, Dralle\u00a0H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J\u00a0Clin Endocrinol Metab 95:2655\u20132663","journal-title":"J Clin Endocrinol Metab"},{"key":"1728_CR50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1530\/EJE-16-0325","volume":"175","author":"A Machens","year":"2016","unstructured":"Machens\u00a0A, Dralle\u00a0H (2016) Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol 175:219\u2013228","journal-title":"Eur J Endocrinol"},{"key":"1728_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00423-019-01764-3","volume":"404","author":"F Torresan","year":"2019","unstructured":"Torresan\u00a0F, Mian\u00a0C, Cavedon\u00a0E, Iacobone\u00a0M (2019) Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening. Langenbecks Arch Surg 404:411\u2013419","journal-title":"Langenbecks Arch Surg"},{"key":"1728_CR52","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","volume":"20","author":"R Ciampi","year":"2019","unstructured":"Ciampi\u00a0R et\u00a0al (2019) Genetic landscape of somatic mutations in a\u00a0large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience 20:324\u2013336","journal-title":"iScience"},{"key":"1728_CR53","doi-asserted-by":"publisher","first-page":"9875","DOI":"10.18632\/oncotarget.23986","volume":"9","author":"C Romei","year":"2018","unstructured":"Romei\u00a0C et\u00a0al (2018) RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. Oncotarget 9:9875","journal-title":"Oncotarget"},{"key":"1728_CR54","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells","year":"2015","unstructured":"Wells\u00a0SA et\u00a0al (2015) Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567\u2013610","journal-title":"Thyroid"},{"key":"1728_CR55","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa077","author":"T Vogel","year":"2020","unstructured":"Vogel\u00a0T et\u00a0al (2020) Bone metastases in medullary thyroid carcinoma: high morbidity and poor prognosis associated with osteolytic morphology. J\u00a0Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa077","journal-title":"J Clin Endocrinol Metab"},{"key":"1728_CR56","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei\u00a0R et\u00a0al (2013) Cabozantinib in progressive medullary thyroid cancer. J\u00a0Clin Oncol 31:3639\u20133646","journal-title":"J. Clin. Oncol."},{"key":"1728_CR57","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells","year":"2012","unstructured":"Wells\u00a0SA et\u00a0al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a\u00a0randomized, double-blind phase\u00a0III trial. J\u00a0Clin Oncol 30:134\u2013141","journal-title":"J. Clin. Oncol."},{"key":"1728_CR58","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0206","author":"VF Koehler","year":"2020","unstructured":"Koehler\u00a0VF et\u00a0al (2020) Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer. Thyroid. https:\/\/doi.org\/10.1089\/thy.2020.0206","journal-title":"Thyroid"},{"key":"1728_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143405","author":"VF Koehler","year":"2022","unstructured":"Koehler\u00a0VF et\u00a0al (2022) Treatment of RET-positive advanced medullary thyroid cancer with multi-tyrosine kinase inhibitors\u2014a retrospective multi-center registry analysis. Cancers. https:\/\/doi.org\/10.3390\/cancers14143405","journal-title":"Cancers"},{"key":"1728_CR60","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","volume":"389","author":"J Hadoux","year":"2023","unstructured":"Hadoux\u00a0J et\u00a0al (2023) Phase\u00a03 trial of selpercatinib in advanced RET\u2014mutant medullary thyroid cancer. N\u00a0Engl J Med 389:1851\u20131861","journal-title":"N Engl J Med"},{"key":"1728_CR61","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"Subbiah\u00a0V et\u00a0al (2021) Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a\u00a0multi-cohort, open-label, registrational, phase\u00a01\/2\u00a0study. Lancet Diabetes Endocrinol 9:491\u2013501","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1728_CR62","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","volume":"31","author":"JJ Lin","year":"2020","unstructured":"Lin\u00a0JJ et\u00a0al (2020) Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol 31:1725\u20131733","journal-title":"Ann Oncol"},{"key":"1728_CR63","first-page":"1","volume":"13","author":"EY Rosen","year":"2022","unstructured":"Rosen\u00a0EY et\u00a0al (2022) The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nat Commun 13:1\u20139","journal-title":"Nat Commun"},{"key":"1728_CR64","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","volume":"32","author":"V Subbiah","year":"2021","unstructured":"Subbiah\u00a0V et\u00a0al (2021) Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol 32:261\u2013268","journal-title":"Ann Oncol"},{"key":"1728_CR65","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","volume":"15","author":"BJ Solomon","year":"2020","unstructured":"Solomon\u00a0BJ et\u00a0al (2020) RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J\u00a0Thorac Oncol 15:541\u2013549","journal-title":"J Thorac Oncol"},{"key":"1728_CR66","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/542358","author":"SC Remick","year":"2011","unstructured":"Remick\u00a0SC, Nagaiah\u00a0G, Hossain\u00a0A, Mooney\u00a0CJ, Parmentier\u00a0J (2011) Anaplastic thyroid cancer: a\u00a0review of epidemiology, pathogenesis, and treatment. J\u00a0Oncol. https:\/\/doi.org\/10.1155\/2011\/542358","journal-title":"J Oncol"},{"key":"1728_CR67","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1089\/thy.2017.0102","volume":"27","author":"RM Tuttle","year":"2017","unstructured":"Tuttle\u00a0RM, Haugen\u00a0B, Perrier\u00a0ND (2017) Updated American joint committee on cancer\/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid 27:751","journal-title":"Thyroid"},{"key":"1728_CR68","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa\u00a0I et\u00a0al (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J\u00a0Clin Invest 126:1052\u20131066","journal-title":"J Clin Invest"},{"key":"1728_CR69","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12020-016-1080-9","volume":"54","author":"S Latteyer","year":"2016","unstructured":"Latteyer\u00a0S et\u00a0al (2016) Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine 54:733\u2013741","journal-title":"Endocrine"},{"key":"1728_CR70","doi-asserted-by":"publisher","first-page":"42613","DOI":"10.18632\/oncotarget.17300","volume":"8","author":"V Tiedje","year":"2017","unstructured":"Tiedje\u00a0V et\u00a0al (2017) NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. Oncotarget 8:42613\u201342620","journal-title":"Oncotarget"},{"key":"1728_CR71","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1530\/ERC-17-0435","volume":"25","author":"V Tiedje","year":"2018","unstructured":"Tiedje\u00a0V et\u00a0al (2018) Anaplastic thyroid carcinoma: review of treatment protocols. Endocr Relat Cancer 25:R153\u2013R161. https:\/\/doi.org\/10.1530\/ERC-17-0435","journal-title":"Endocr Relat Cancer"},{"key":"1728_CR72","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1530\/EJE-16-0574","volume":"175","author":"J Wendler","year":"2016","unstructured":"Wendler\u00a0J et\u00a0al (2016) Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a\u00a0multicenter study in Germany. Eur J Endocrinol 175:521\u2013529","journal-title":"Eur J Endocrinol"},{"key":"1728_CR73","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1089\/thy.2013.0078","volume":"24","author":"JA Sosa","year":"2014","unstructured":"Sosa\u00a0JA et\u00a0al (2014) Randomized safety and efficacy study of fosbretabulin with paclitaxel\/carboplatin against anaplastic thyroid carcinoma. Thyroid 24:232\u2013240","journal-title":"Thyroid"},{"key":"1728_CR74","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1089\/thy.2016.0621","volume":"27","author":"Y Ito","year":"2017","unstructured":"Ito\u00a0Y et\u00a0al (2017) Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid 27:1142\u20131148","journal-title":"Thyroid"},{"key":"1728_CR75","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2017.01.029","volume":"76","author":"A Ravaud","year":"2017","unstructured":"Ravaud\u00a0A et\u00a0al (2017) A\u00a0multicenter phase\u00a0II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer 76:110\u2013117","journal-title":"Eur J Cancer"},{"key":"1728_CR76","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1210\/jc.2012-1520","volume":"97","author":"KC Bible","year":"2012","unstructured":"Bible\u00a0KC et\u00a0al (2012) A\u00a0multiinstitutional phase\u00a02\u00a0trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J\u00a0Clin Endocrinol Metab 97:3179\u20133184","journal-title":"J Clin Endocrinol Metab"},{"key":"1728_CR77","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1200\/JCO.20.03093","volume":"39","author":"LJ Wirth","year":"2021","unstructured":"Wirth\u00a0LJ et\u00a0al (2021) Open-label, single-arm, multicenter, phase\u00a0II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J\u00a0Clin Oncol 39:2359\u20132366","journal-title":"J Clin Oncol"},{"key":"1728_CR78","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/ERC-20-0106","volume":"28","author":"C Sparano","year":"2021","unstructured":"Sparano\u00a0C et\u00a0al (2021) Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a\u00a0French overview. Endocr Relat Cancer 28:15\u201326","journal-title":"Endocr Relat Cancer"},{"key":"1728_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00599","author":"SY Kim","year":"2020","unstructured":"Kim\u00a0SY et\u00a0al (2020) Survival with lenvatinib for the treatment of progressive anaplastic thyroid cancer: a\u00a0single-center, retrospective analysis. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2020.00599","journal-title":"Front Endocrinol"},{"key":"1728_CR80","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12020-020-02425-y","volume":"71","author":"M Kim","year":"2021","unstructured":"Kim\u00a0M et\u00a0al (2021) Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer. Endocrine 71:427\u2013433","journal-title":"Endocrine"},{"key":"1728_CR81","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1007\/s12325-020-01433-8","volume":"37","author":"S Takahashi","year":"2020","unstructured":"Takahashi\u00a0S et\u00a0al (2020) Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan. Adv Ther 37:3850\u20133862","journal-title":"Adv Ther"},{"key":"1728_CR82","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","volume":"33","author":"S Filetti","year":"2022","unstructured":"Filetti\u00a0S et\u00a0al (2022) ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol 33:674\u2013684","journal-title":"Ann Oncol"},{"key":"1728_CR83","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible\u00a0KC et\u00a0al (2021) 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31:337\u2013386","journal-title":"Thyroid"},{"key":"1728_CR84","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah\u00a0V et\u00a0al (2018) Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer. J\u00a0Clin Oncol 36:7\u201313","journal-title":"J. Clin. Oncol."},{"key":"1728_CR85","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah\u00a0V et\u00a0al (2023) Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase\u00a02 ROAR trial. Nat Med 29:1103\u20131112","journal-title":"Nat Med"},{"key":"1728_CR86","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1089\/thy.2019.0133","volume":"29","author":"JR Wang","year":"2019","unstructured":"Wang\u00a0JR et\u00a0al (2019) Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid 29:1036\u20131043","journal-title":"Thyroid"},{"key":"1728_CR87","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas\u00a0A et\u00a0al (2020) Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019. JAMA Oncol 6:1397\u20131404","journal-title":"JAMA Oncol"},{"key":"1728_CR88","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong\u00a0DS et\u00a0al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a\u00a0pooled analysis of three phase\u00a01\/2 clinical trials. Lancet Oncol 21:531","journal-title":"Lancet Oncol"},{"key":"1728_CR89","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack\u00a0SG et\u00a0al (2022) Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 186:631\u2013643","journal-title":"Eur J Endocrinol"},{"key":"1728_CR90","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele\u00a0RC et\u00a0al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase\u00a01\u20132\u00a0trials. Lancet Oncol 21:271\u2013282","journal-title":"Lancet Oncol"},{"key":"1728_CR91","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","volume":"28","author":"GD Demetri","year":"2022","unstructured":"Demetri\u00a0GD et\u00a0al (2022) Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 28:1302\u20131312","journal-title":"Clin Cancer Res"},{"key":"1728_CR92","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila\u00a0J et\u00a0al (2020) PD\u20111 blockade in anaplastic thyroid carcinoma. J\u00a0Clin Oncol 38:2620\u20132627","journal-title":"J. Clin. Oncol."},{"key":"1728_CR93","doi-asserted-by":"publisher","first-page":"6513","DOI":"10.1200\/JCO.2020.38.15_suppl.6513","volume":"38","author":"JH Lorch","year":"2020","unstructured":"Lorch\u00a0JH et\u00a0al (2020) A\u00a0phase\u00a0II study of nivolumab (N) plus ipilimumab (I)\u00a0in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC). J\u00a0Clin Oncol 38:6513\u20136513","journal-title":"J. Clin. Oncol."},{"key":"1728_CR94","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks\u00a0C et\u00a0al (2021) Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 31:1076\u20131085","journal-title":"Thyroid"},{"key":"1728_CR95","unstructured":"OncologyPRO Phase\u00a0II ATLEP trial: final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress\/phase-ii-atlep-trial-final-results-for-lenvatinib-pembrolizumab-in-metastasized-anaplastic-and-poorly-differentiated-thyroid-carcinoma"},{"key":"1728_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-024-01555-y","volume":"24","author":"D Soll","year":"2024","unstructured":"Soll\u00a0D et\u00a0al (2024) First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a\u00a0retrospective cohort study. BMC Endocr Disord 24:1\u20139","journal-title":"BMC Endocr Disord"},{"key":"1728_CR97","doi-asserted-by":"publisher","first-page":"A-136","DOI":"10.1089\/thy.2022.29140.lb.abstracts","volume":"32","author":"M Bojarsky","year":"2022","unstructured":"Bojarsky\u00a0M et\u00a0al (2022) Late breaking abstracts. Thyroid 32:A-136\u2013A-174","journal-title":"Thyroid"},{"key":"1728_CR98","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1200\/JCO.2020.38.15_suppl.6514","volume":"38","author":"ME Cabanillas","year":"2020","unstructured":"Cabanillas\u00a0ME et\u00a0al (2020) Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). J\u00a0Clin Oncol 38:6514\u20136514","journal-title":"J. Clin. Oncol."}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01728-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:03:49Z","timestamp":1719385429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01728-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":98,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1728"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01728-w","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"15 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T. Brandenburg erkl\u00e4rt finanzielle Verbindungen zu Eisai (Vortragshonorare und Advisory Boards), zu Lilly (Vortragshonorare, Advisory Boards und Beratert\u00e4tigkeiten sowie die Teilnahme an klinischen Studien) und zu Bayer Pharma (Advisory Boards). M. Kroi\u00df gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}